Antral follicle count and anti-Mullerian hormone to classify low-prognosis women under the POSEIDON criteria: a classification agreement study of over 9000 patients

Creative Commons License

Esteves S. C., Yarali H., Vuong L. N., Carvalho J. F., Ozbek I. Y., Polat M., ...More

HUMAN REPRODUCTION, vol.36, no.6, pp.1530-1541, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 36 Issue: 6
  • Publication Date: 2021
  • Doi Number: 10.1093/humrep/deab056
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, CINAHL, EMBASE, Gender Studies Database, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.1530-1541
  • Keywords: assisted reproductive technology, antral follicle count, anti-Mullerian hormone, POSEIDON criteria, agreement study, low prognosis, poor 90 response, IVF/ICSI, CONTROLLED OVARIAN STIMULATION, ANTIMULLERIAN HORMONE, INTEROBSERVER RELIABILITY, 3-DIMENSIONAL ULTRASOUND, ANTAGONIST PROTOCOL, PREDICTION, RESERVE, VARIABILITY, INTRAOBSERVER, CYCLE
  • Hacettepe University Affiliated: Yes


STUDY QUESTION: What is the agreement between antral follicle count (AFC) and anti-Mullerian hormone (AMH) levels when used to patient classification according to the Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number (POSEIDON) criteria?